UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AS-924, a Novel Orally Active Bifunctional Prodrug of Ceftizoxime. Synthesis and Relationship between Physicochemical Properties and Oral Absorption

Chemical and Pharmaceutical Bulletin, 1999/08/15, Vol.47(8), pp.1081-1088

1999

Volltextzugriff (PDF)

AS-924, a Novel Bifunctional Prodrug of Ceftioxime

Journal of antibiotics, 1999, Vol.52 (5), p.491-500

1999

Volltextzugriff (PDF)

Absorption Mechanism of 1, 3-Bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate

Biological and Pharmaceutical Bulletin, 1993/04/15, Vol.16(4), pp.375-378

1993

Volltextzugriff (PDF)

Studies on the Promoting Effects of Carboxylic Acid Derivatives on the Rectal Absorption of β-Lactam Antibiotics in Rats

Chemical and Pharmaceutical Bulletin, 1985/01/25, Vol.33(1), pp.282-291

1985

Volltextzugriff (PDF)

AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity

International journal of antimicrobial agents, 2001-11, Vol.18 (5), p.451-461

2001

Volltextzugriff (PDF)

Erratum to “AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity”: [International Journal of Antimicrobial Agents 18 (2001) 451–461]

International journal of antimicrobial agents, 2002-05, Vol.19 (5), p.439-442

2002

Volltextzugriff (PDF)

AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity : Pharmacokinetic evaluation of a novel bifunctional prodrug of ceftizoxime-AS-924

International journal of antimicrobial agents, 2001, Vol.18 (5), p.451-461

2001

Volltextzugriff (PDF)

AS-924, a Novel Bifunctional Prodrug of Ceftizoxime

The Journal of Antibiotics, 1999/05/25, Vol.52(5), pp.491-500

1999

Volltextzugriff (PDF)

Characteristics of 1, 3-Bis-(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy) propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate, in Absorption and Excretion in Rats and Rabbits

Journal of Pharmacobio-Dynamics, 1992, Vol.15(12), pp.681-686

1992

Volltextzugriff (PDF)

Studies on the Promoting Effects of Carboxylic Acid Derivatives on the Rectal Absorption of [beta]-Lactam Antibiotics in Rats

Chemical & pharmaceutical bulletin, 1985-01, Vol.33 (1), p.282

1985

Volltextzugriff (PDF)

ChemInform Abstract: AS-924, a Novel Bifunctional Prodrug of Ceftizoxime

ChemInform, 1999-10, Vol.30 (42), p.no-no

1999

Volltextzugriff (PDF)

EFFECTS OF CEFTIZOXIME SUPPOSITORY RECTAL DOSING ON CECAL MICROFLORA IN MICE

The Japanese Journal of Antibiotics, 1986/01/25, Vol.39(1), pp.94-98

1986

Volltextzugriff (PDF)

EFFECTS OF AMPICILLIN SUPPOSITORY (KS-RI) RECTAL DOSING ON CECAL MICROFLORA AND CECAL WEIGHTS IN MICE

The Japanese Journal of Antibiotics, 1983/07/25, Vol.36(7), pp.1699-1705

1983

Volltextzugriff (PDF)

PHARMACOKINETICS OF CEFTIZOXIME SUPPOSITORY IN EXPERIMENTAL ANIMALS

The Japanese Journal of Antibiotics, 1985/12/25, Vol.38(12), pp.3449-3457

1985

Volltextzugriff (PDF)

PHARMACOKINETICS OF AMPICILLIN SUPPOSITORY (KS-R1) IN MICE, RATS AND RABBITS

The Japanese Journal of Antibiotics, 1983/07/25, Vol.36(7), pp.1683-1691

1983

Volltextzugriff (PDF)

Ceftizoxime坐剤の実験動物における体内動態について

The Japanese Journal of Antibiotics, 1985/12/25, Vol.38(12), pp.3449-3457

1985

Volltextzugriff (PDF)

アンピシリン坐剤 (KS-R1) 直腸内投与時のマウス盲腸内菌叢及び盲腸重量に及ぼす影響

The Japanese Journal of Antibiotics, 1983/07/25, Vol.36(7), pp.1699-1705

1983

Volltextzugriff (PDF)

アンピシリン坐剤 (KS-R1) のマウス, ラット及びウサギにおける体内動態

The Japanese Journal of Antibiotics, 1983/07/25, Vol.36(7), pp.1683-1691

1983

Volltextzugriff (PDF)

A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors

Nature communications, 2022-08, Vol.13 (1), p.4478-4478, Article 4478

2022

Volltextzugriff (PDF)

Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.11110-11110

2024

Volltextzugriff (PDF)

RARE-03. GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION AT BAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i33-i34

2023

Volltextzugriff (PDF)

Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study

Journal of gastroenterology, 2024-03, Vol.59 (3), p.195-208

2024

Volltextzugriff (PDF)

BOT-3 GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION AT BAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

Neuro-oncology advances, 2022-12, Vol.4 (Supplement_3), p.iii7-iii7

2022

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(18)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Animals
(9)
Science & Technology
(9)
Life Sciences & Biomedicine
(8)
Male
(8)
Pharmacology & Pharmacy
(6)
Rats
(6)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Pharmacology. Drug Treatments
(5)
Prodrugs - Pharmacokinetics
(5)
Rabbits
(5)
Administration, Oral
(4)
Antibacterial Agents
(4)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(4)
Ceftizoxime
(4)
Dogs
(4)
Intestinal Absorption
(4)
Mice
(4)
Suppositories
(4)
As-924
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AS-924, a Novel Orally Active Bifunctional Prodrug of Ceftizoxime. Synthesis and Relationship between Physicochemical Properties and Oral Absorption

AS-924, a Novel Bifunctional Prodrug of Ceftioxime

Absorption Mechanism of 1, 3-Bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate

Studies on the Promoting Effects of Carboxylic Acid Derivatives on the Rectal Absorption of β-Lactam Antibiotics in Rats

AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity

Erratum to “AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity”: [International Journal of Antimicrobial Agents 18 (2001) 451–461]

AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity : Pharmacokinetic evaluation of a novel bifunctional prodrug of ceftizoxime-AS-924

AS-924, a Novel Bifunctional Prodrug of Ceftizoxime

Characteristics of 1, 3-Bis-(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy) propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate, in Absorption and Excretion in Rats and Rabbits

Studies on the Promoting Effects of Carboxylic Acid Derivatives on the Rectal Absorption of [beta]-Lactam Antibiotics in Rats

ChemInform Abstract: AS-924, a Novel Bifunctional Prodrug of Ceftizoxime

EFFECTS OF CEFTIZOXIME SUPPOSITORY RECTAL DOSING ON CECAL MICROFLORA IN MICE

EFFECTS OF AMPICILLIN SUPPOSITORY (KS-RI) RECTAL DOSING ON CECAL MICROFLORA AND CECAL WEIGHTS IN MICE

PHARMACOKINETICS OF CEFTIZOXIME SUPPOSITORY IN EXPERIMENTAL ANIMALS

PHARMACOKINETICS OF AMPICILLIN SUPPOSITORY (KS-R1) IN MICE, RATS AND RABBITS

Ceftizoxime坐剤の実験動物における体内動態について

アンピシリン坐剤 (KS-R1) 直腸内投与時のマウス盲腸内菌叢及び盲腸重量に及ぼす影響

アンピシリン坐剤 (KS-R1) のマウス, ラット及びウサギにおける体内動態

A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors

Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial

Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force

RARE-03. GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION AT BAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study

BOT-3 GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION AT BAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

Suchergebnisse filtern